Amandine Charreton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amandine Charreton has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Alain Puisieux
Centre Léon Bérard, Lyon, France
85 shared publications - Alain Viari
Bioinformatics Platform Gilles Thomas, Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1 , Synergie Lyon Cancer Fondation, 69008 Lyon
85 shared publications - Anne Floquet
GINECO (Groupe d’Investigateurs Nationaux pour l’Etude des Cancers de l’Ovaire, Paris, France
85 shared publications - Anne-Pierre Morel
Centre L eon B erard, Cancer Research Centre of Lyon, Equipe Labellis ee Ligue contre le Cancer, Lyon, France
85 shared publications - Anne-Sophie Sertier
Synergie Lyon Cancer, Plateforme de bioinformatique Gilles Thomas, Centre Léon Bérard, Lyon, France
85 shared publications - Anthony Ferrari
Synergie Lyon Cancer, Plateforme de bioinformatique Gilles Thomas, Centre Léon Bérard, Lyon, France
85 shared publications
Latest Publications
- Open Access
PERIGENOMED-CLINICS 1—the first study on feasibility, acceptability and psychosocial impact of PERIGENOMED: a pilot project aimed at providing initial concrete evidence on the relevance of panel-based genome sequencing for newborn screening (NBS) in France
Introduction International pilot projects focusing on next-generation sequencing in newborn screening (NBS), that is, genomic NBS (gNBS), have been established thanks to continuous therapeutic progress and the massive development of new genetic technologies with rapidly decreasing costs. Given the highly encouraging results of the French SeDeN project regarding anticipated acceptability among professionals and parents, it is now appropriate to launch a similar pilot project in France, in collaboration with other international initiatives under the International Consortium on Newborn Sequencing framework. Methods and analysis PERIGENOMED is a large-scale project designed to provide the first concrete evidence on the relevance of gNBS in France. It includes two clinical trials. We present here the design chosen for the first clinical trial (PERIGENOMED-CLINICS 1). PERIGENOMED-CLINICS 1 aims to assess the feasibility, real-world acceptability, psychosocial impact and organisational pathways of panel-based genomic newborn screening in France, involving 2500 participants. Solo-GS targeting two lists of gene–disease dyads responsible for treatable (list 1; 400 genes, 171 diseases/group of diseases) or actionable (list 2 optional; 407 genes, 218 diseases/group of diseases) rare and severe early-onset diseases will be proposed in five health institutions. Ancillary social and impact studies will also be included. Ethics and dissemination All study procedures have been reviewed and approved by relevant French ethics committees and regulatory authorities (CPP Est II-2024-A02224-43, 1 January 2025). Results of the project will be disseminated through peer-reviewed publications, national and international conferences, and public engagement initiatives, in coordination with stakeholders. Trial registration number NCT06875089.
Open AccessPERIGENOMED-CLINICS 1—the first study on feasibility, acceptability and psychosocial impact of PERIGENOMED: a pilot project aimed at providing initial concrete evidence on the relevance of panel-based genome sequencing for newborn screening (NBS) in France
Introduction International pilot projects focusing on next-generation sequencing in newborn screening (NBS), that is, genomic NBS (gNBS), have been established thanks to continuous therapeutic progress and the massive development of new genetic technologies with rapidly decreasing costs. Given the highly encouraging results of the French SeDeN project regarding anticipated acceptability among professionals and parents, it is now appropriate to launch a similar pilot project in France, in collaboration with other international initiatives under the International Consortium on Newborn Sequencing framework. Methods and analysis PERIGENOMED is a large-scale project designed to provide the first concrete evidence on the relevance of gNBS in France. It includes two clinical trials. We present here the design chosen for the first clinical trial (PERIGENOMED-CLINICS 1). PERIGENOMED-CLINICS 1 aims to assess the feasibility, real-world acceptability, psychosocial impact and organisational pathways of panel-based genomic newborn screening in France, involving 2500 participants. Solo-GS targeting two lists of gene–disease dyads responsible for treatable (list 1; 400 genes, 171 diseases/group of diseases) or actionable (list 2 optional; 407 genes, 218 diseases/group of diseases) rare and severe early-onset diseases will be proposed in five health institutions. Ancillary social and impact studies will also be included. Ethics and dissemination All study procedures have been reviewed and approved by relevant French ethics committees and regulatory authorities (CPP Est II-2024-A02224-43, 1 January 2025). Results of the project will be disseminated through peer-reviewed publications, national and international conferences, and public engagement initiatives, in coordination with stakeholders. Trial registration number NCT06875089.
- Open Access
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
List of differentially expressed genes (paired analysis of 5 selected tumors).
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
List of differentially expressed genes (paired analysis of 5 selected tumors).
- Open Access
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
List of differentially methylated gene promoters (paired analysis of 5 selected tumors).
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
List of differentially methylated gene promoters (paired analysis of 5 selected tumors).
- Open Access
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Figure S7 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Alteration of chromatin remodeling genes in uterine and ovarian CS.
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Alteration of chromatin remodeling genes in uterine and ovarian CS.
- Open Access
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Genomic landscape of CS. A, Tissue origin and histological subtypes for each tumor (from P01 to P15). B, Main component and detailed percentage content for both samples (a and b) derived from the same tumor. C, CNA analysis: tumor purity (%), ploidy, FGA, and CNA breakpoints number. D, SV number, classified as deletion, duplication, inversion, and interchromosomal translocation. E, SNV and small indel number. F, Proportion of each of four mutational signatures deciphered in the whole cohort. G, MSI phenotype: MSI score (representing the percentage of unstable microsatellite loci), MLH1 promoter methylation (beta-value), and mRNA expression level (TPM – transcripts per million). H, Kataegis number illustrating APOBEC error-prone DNA repair process. I, BRCAness phenotype: number of LST, (white stars highlight samples with LST number ≥20), BRCA1 promoter methylation level (beta-value), BRCA1/2 genes alterations and TDP score, collectively summarized by the HRD status track.
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Genomic landscape of CS. A, Tissue origin and histological subtypes for each tumor (from P01 to P15). B, Main component and detailed percentage content for both samples (a and b) derived from the same tumor. C, CNA analysis: tumor purity (%), ploidy, FGA, and CNA breakpoints number. D, SV number, classified as deletion, duplication, inversion, and interchromosomal translocation. E, SNV and small indel number. F, Proportion of each of four mutational signatures deciphered in the whole cohort. G, MSI phenotype: MSI score (representing the percentage of unstable microsatellite loci), MLH1 promoter methylation (beta-value), and mRNA expression level (TPM – transcripts per million). H, Kataegis number illustrating APOBEC error-prone DNA repair process. I, BRCAness phenotype: number of LST, (white stars highlight samples with LST number ≥20), BRCA1 promoter methylation level (beta-value), BRCA1/2 genes alterations and TDP score, collectively summarized by the HRD status track.
- Open Access
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Figure S16 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Complete clonal evolution of P15 tumor.
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S16 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Complete clonal evolution of P15 tumor.
- Open Access
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
BRCAness feature: tandem duplicator phenotype.
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
BRCAness feature: tandem duplicator phenotype.
- Open Access
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Figure S9 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Clustering of somatic copy number alterations profiles.
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Clustering of somatic copy number alterations profiles.
- Open Access
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Figure S8 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Alteration of genes of RAS pathway in uterine and ovarian CS.
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Alteration of genes of RAS pathway in uterine and ovarian CS.
- Open Access
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Figure S13 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Complete clonal evolution of P01 tumor.
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S13 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Complete clonal evolution of P01 tumor.